Spectris plc (LON: SXS), the precision‑measurement specialist, is effectively at the end of its life as a London‑listed share. On 3 December 2025, investors are trading SXS for the final time before a court‑sanctioned takeover by KKR’s Project Aurora Bidco becomes effective and the stock is delisted from the London Stock Exchange later this week.
Below is a full rundown of the latest share price, the KKR deal mechanics, key dates, analyst forecasts and what it all means for shareholders on 3 December 2025.
Spectris share price today: trading in the takeover “zone”
As of the morning of 3 December 2025, Spectris shares are changing hands at around 4,142–4,143 pence (about £41.42–£41.43) on the London Stock Exchange. That leaves the stock trading just a fraction below the £41.75 per share cash offer from KKR.
Key snapshot:
- Current price (approx.): 4,143p
- 12‑month change: roughly +64%, after a year dominated by competing private‑equity bids from Advent International and KKR.
- 52‑week range: about 1,880p–4,170p, with the high set after the takeover battle kicked off.
In practical terms, the share price is no longer reacting to day‑to‑day fundamentals. It’s behaving like a classic “deal stock”: pinned near the agreed offer price, with tiny moves reflecting only:
- the small remaining spread between market price and deal consideration
- the market’s estimate of residual deal risk (now very low after court sanction)
KKR’s £41.75 per share offer: how we got here
The takeover story has been one of the biggest UK M&A sagas of 2025:
- Early 2025: Advent International and KKR both circle Spectris, attracted by a high‑quality industrial technology business that public markets had arguably under‑valued.
- June–July: Advent secures board support for an offer worth about £37.63 per share including dividend. KKR then counters with a higher proposal.
- 2 July 2025: Spectris and KKR’s Project Aurora Bidco announce a recommended cash offer, initially at a lower level than today’s final terms.
- 5 August 2025: KKR ups the ante with an increased cash offer of £41.75 per share, split into £41.47 in cash plus a 28p interim dividend. The Spectris board unanimously recommends the deal and drops support for Advent.
- 27 August 2025: Shareholders overwhelmingly approve the scheme of arrangement at the Court Meeting and General Meeting; over 99.9% of votes cast back the KKR deal.
The transaction values Spectris’ equity at roughly £4.1–4.2 billion and the enterprise at about £4.7–4.8 billion, with KKR paying close to a 100% premium to the pre‑bid share price.
KKR’s thesis, as outlined in deal documents and press coverage, is straightforward: Spectris is a high‑quality, cash‑generative instrumentation and testing group operating in attractive end markets (pharma, semiconductors, advanced materials), and there’s more value to be unlocked via long‑term investment and bolt‑on acquisitions away from the short‑term pressures of public markets.
Court sanction and timetable: what changes on 3–5 December 2025?
The structure of the deal is a UK scheme of arrangement under Part 26 of the Companies Act 2006. The last major hurdle was the court hearing.
- 2 December 2025 – Court Sanction:
The High Court formally sanctioned the scheme of arrangement for the KKR takeover. Spectris confirmed that applications have been made to suspend trading and cancel the listing, with only mechanical steps left (filing the Court Order with the Registrar of Companies). - Updated timetable (from Spectris’ 24 November RNS and court‑sanction announcement):Research Tree+2Investegate+2
- 3 December 2025:
- Last day of dealings in Spectris shares on the LSE main market
- Scheme Record Time at 6:00 p.m. – only shareholders on the register at this time receive the cash consideration
- 4 December 2025 (expected Effective Date):
- Scheme becomes effective when the Court Order is delivered to the Registrar of Companies
- Trading in SXS shares suspended from 7:30 a.m.
- 5 December 2025:
- Delisting – Spectris shares are expected to be removed from the Official List and from trading on the London Stock Exchange by 7:30 a.m.
- Within 14 days of the Effective Date:
- Cash consideration is expected to be paid to shareholders (via CREST credits or cheques).
- 3 December 2025:
Spectris has also confirmed that all required antitrust and foreign‑investment approvals have been obtained in key jurisdictions such as France, the Netherlands and Spain, meaning the main conditions left are purely procedural.
For all practical purposes, then, 3 December is the last day retail investors can freely buy or sell SXS on the exchange before it becomes a private company owned by KKR.
What exactly do Spectris shareholders receive?
Under the final agreed terms, each Spectris shareholder is entitled to an offer value of £41.75 per share, composed of:
- £41.47 in cash from KKR’s Bidco
- 28p interim dividend paid by Spectris (already declared and treated as part of the offer value)
A few practical points that matter on 3 December:
- You must be on the share register at the Scheme Record Time (6:00 p.m., 3 December) to receive the scheme consideration.
- From the Effective Date (4 December), your shares cease to exist as tradable equity and are replaced by a right to receive cash. Share certificates become invalid, and CREST positions are cancelled.
- Payment is due within 14 days of effectiveness, which is standard for UK schemes.
Operational backdrop: Spectris is being sold from a position of strength, not distress
The takeover isn’t happening because Spectris was broken. If anything, the operating trends in 2025 strengthened the case that KKR is paying up for a quality platform.
Half‑year 2025 results
For the six months to 30 June 2025, Spectris reported:
- Sales: £636.1m vs £589.7m in H1 2024
- +8% reported growth, +1% like‑for‑like
- Adjusted operating profit: £65.6m (up from £61.1m), with margins around 10.3%
- Profit Improvement Programme:
- >£10m of savings already realised in H1
- >£30m of savings expected for the full year 2025
- Net debt: £546m, with leverage expected to return to the 1–2x target range by year‑end
The board explicitly said it expected full‑year adjusted operating profit to be in line with management expectations and highlighted that the KKR offer valued the company at a significant premium to stand‑alone fair value.
Q3 2025 trading update
The third‑quarter update on 30 October 2025 showed the momentum continuing:
- Q3 sales: £335.6m, vs £302.7m in Q3 2024
- +11% reported, +4% like‑for‑like
- Spectris Scientific: +12% reported, +5% like‑for‑like
- Spectris Dynamics: +10% reported, +4% like‑for‑like
- Guidance reiterated: full‑year adjusted operating profit still expected to be in line with management expectations
In the same Q3 statement, management described the KKR deal as being in an “advanced stage of preparation for completion”, setting the stage for November’s regulatory clearance and the December court sanction. Spectris+1
Analyst forecasts on 3 December 2025: fundamentals vs takeover price
Here’s where the story gets interesting. With Spectris now trading at roughly 4,142p, almost all traditional valuation work has become a “what if the deal fails?” exercise.
Consensus price targets from major data providers
As of 3 December 2025, various platforms show broadly similar fundamentals‑based price targets:
- Financial Times (7 analysts):
- Median 12‑month target: 3,135p
- High: 4,175p
- Low: 2,250p
- Median implies about 24% downside from the last price of 4,142p.
- Investing.com (6 analysts):
- Average target: 3,536.7p
- High: 4,175p
- Low: 3,000p
- Overall consensus rating: “Buy”. Investing.com
- MarketBeat (3 analysts):
- Average target: 3,573.5p
- Range: 3,000–4,147p
- Implied –13.7% downside vs the current share price of 4,142p.
- Fintel:
- Average one‑year target: 3,365.3p
- Range: 2,272.5–4,383.8p.
- MarketScreener (8 analysts):
- Average target: £35.37 (~3,537p)
- High target: £41.75 (the KKR bid)
- Low target: £30.00
- Implied –14–15% downside vs a last close of £41.42.
- TipRanks (most deal‑aware snapshot):
- Average target: 4,147p
- Based on a single very recent 12‑month target aligned almost exactly with the takeover price
- Shows ~0.3% upside from a current price around 4,134p and a “Hold” consensus. TipRanks
TS2 Tech’s synthesis of these sources lands in the same place: most fundamental models put standalone fair value somewhere in the low‑to‑mid £30s, well below both the trading range and the £41.75 offer.
In plain language:
- Without the KKR bid, analysts generally thought Spectris was worth ~£30–35 per share.
- With the KKR bid, the market price has been pulled up to ~£41–42, near the £41.75 offer.
That gap is exactly the control premium KKR is paying.
So is Spectris still a buy on 3 December 2025?
For new investors, SXS at this point isn’t really an ordinary “stock idea” – it’s a very short‑dated merger‑arbitrage trade:
- Upside:
- Roughly the tiny spread between today’s price (~£41.42–£41.43) and the £41.75 cash payout – well under 1%.
- You get that return only if the scheme becomes effective as expected around 4 December.
- Downside:
- If the deal somehow collapsed at this late stage, the share price would likely fall back towards standalone fair‑value estimates or pre‑bid levels, probably in the low‑to‑mid £30s or worse, given where it traded before the Advent and KKR offers emerged.
The market is signalling that the probability of failure is very low – that’s why the spread is tiny – but it is not literally zero until the Court Order is filed and cash lands in accounts.
For existing shareholders, there are essentially three choices on 3 December:
- Sell today in the market
- You lock in cash immediately at roughly £41.4x per share, slightly below the scheme consideration but without waiting for settlement.
- Hold through completion
- Your shares are cancelled under the scheme and you receive £41.47 in cash plus the 28p dividend, usually within two weeks of the effective date.
- Speculate on deal failure
- This is the contrarian path and would typically only appeal to investors with a very specific thesis about regulatory, legal or financing risk – none of which is currently evident after court sanction and regulatory clearance.
Given the risk/reward profile, the economically rational question on 3 December isn’t “Is Spectris a good business?” (it clearly is), but rather “Do I want to earn maybe 0.5–0.8% in a few days in exchange for a very small probability of a big loss if something freakish happens?”
That’s a probability puzzle, not a traditional value‑investing call.
Why this deal matters beyond Spectris
Zooming out, the Spectris saga has become a poster child for the 2025 wave of UK take‑privates:
- Advent and KKR have both been cited as part of a broader private‑equity buying spree targeting UK mid‑caps perceived as structurally undervalued by public markets.
- The bidding war pushed Spectris to a near‑doubling of its share price from pre‑approach levels, underlining how much value public markets may have been leaving on the table.
- The appointment of Andrew Williams, the former long‑time CEO of Halma, as future chairman of Spectris under KKR reinforces the pattern of pairing financial firepower with seasoned industrial operators to build global platforms in niche technologies.
For UK investors, the Spectris case raises an uncomfortable but important question: how many more high‑quality industrial and technology names will disappear from the London market into private‑equity portfolios?
Final thoughts and disclaimer
On 3 December 2025, Spectris plc is no longer a conventional stock idea. It is:
- A high‑quality industrial technology company with solid recent growth and improving profitability
- Being acquired by KKR at £41.75 per share, nearly double its pre‑bid price
- On its last trading day as a London‑listed share, with delisting expected by 5 December 2025
From here, almost everything that happens to SXS is about legal process and settlement mechanics, not earnings beats or new orders.
